Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 15/20 | 0.38 |
| ▸ | RBBP4 | Q09028 | 15/20 | 0.38 |
| ▸ | SUZ12 | Q15022 | 15/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 15/20 | 0.38 |
| ▸ | AEBP2 | Q6ZN18 | 15/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21251241 | 0.90 | EED (0.40) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21156590 | 0.85 | EED (0.47) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21113098 | 0.84 | EED (0.49) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21113504 | 0.83 | EZH2 (0.36) | EZH2EGFRPDCD1CD274SLC6A2 | |
| SCHEMBL21113505 | 0.83 | EGFR (0.36) | EGFRPDCD1CD274SLC6A2SLC6A4 | |
| SCHEMBL19964847 | 0.79 | EED (0.45) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21156583 | 0.79 | EZH2 (0.44) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL19964872 | 0.77 | EZH2 (0.66) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21157377 | 0.77 | EED (0.46) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL19964875 | 0.77 | EZH2 (0.67) | EEDRBBP4SUZ12EZH2AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20190211010-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO. LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| WO-2018045971-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发有限公司 | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | EZH2, IKZF2, SUZ12 | EED 41/4885RBBP4 288/4885SUZ12 3/4885 |
| US-20190211010-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | EZH2, IKZF2, SUZ12 | EED 41/4885RBBP4 288/4885SUZ12 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.